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Chorea is a rare side effect of anticonvulsants. We describe three patients who developed chorea secondary to anticonvulsant
combination use. A mechanism to explain this finding is proposed.
After identification of an index case with anticonvulsant-induced chorea, we reviewed the electronic data base records for all
patients with seizures followed in the epilepsy clinics at our university-based hospital for cases of dyskinesia associated with
anticonvulsants. Two additional patients, one adult and one pediatric patient were identified.
Three patients developed chorea while receiving combination anticonvulsants. Two patients had transient chorea that resolved
with withdrawal of one of the drugs. All three patients were using phenytoin and lamotrigine in combination when the chorea
started, chorea improved with tapering one of the medications.
Polytherapy with certain anticonvulsants may predispose patients to drug-induced chorea. A particular increased risk was
seen with combinations that have phenytoin and lamotrigine. This could be due to an additive or a synergistic effect on central
dopaminergic pathways.
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INTRODUCTION
Dyskinesias induced by anticonvulsants are a re-
ported side effect1. Most cases have been associated
with phenytoin therapy, although carbamazepine2,
gabapentin3–5, felbamate6 and valproate7 have also
been implicated. Choreoathetosis, dystonia and orofa-
cial dyskinesias have been described1.
We report three patients who developed choreoa-
thetoid movements on anticonvulsants. All those
patients were using phenytoin and lamotrigine in
combination as part of their anticonvulsant regimen
when they developed chorea. No patient had these
movements while on either phenytoin or lamotrigine
monotherapy at normal, or toxic, concentrations.
PATIENTS AND METHOD
After identification of the index case (Patient one), the
electronic database of epilepsy patients was queried
to identify patients with epilepsy and movement dis-
orders. All patients with the diagnosis of epilepsy or
seizures seen in the adult and pediatric clinics between
January 1992 and December 1998 were included.
Searching included any patient with the diagnosis of
epilepsy or seizures and any of the following: move-
ment disorders, chorea, dyskinesia, and ballismus. A
review of these patients found one adult and one
pediatric patient who experienced choreoathetosis.
Information about those patients, including history,
physical examination and laboratory investigation
were reviewed. These cases are presented and the
implications of those findings are discussed.
RESULTS
Case 1
The first patient is a 46-year-old right-handed woman
with intractable right temporal lobe complex partial
seizures, beginning when she was 17 years old.
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1059–1311/01/080596 + 04 $35.00/0 c© 2001 BEA Trading Ltd
Anticonvulsants-induced chorea: a role for pharmacodynamic drug interaction? 597
She had no generalized seizures. She had no
other medical problems and her family history was
negative for seizures or abnormal movements. She
was treated with phenytoin, carbamazepine, primidone
and valproic acid in various combinations. She used
phenytoin (alone and in various combinations, includ-
ing concomitant use with carbamazepine) for almost
15 years without any abnormal movements. Phenytoin
was discontinued secondary to gingival hypertrophy
and lamotrigine was started a few months later and
maintained in combination with carbamazepine. At
lamotrigine level of 14 µg ml−1 she experienced mild
dizziness but no abnormal movements. Two years
later she was evaluated for epilepsy surgery and she
underwent right anterior temporal lobectomy.
Preoperatively she received her daily lamotrigine
and carbamazepine doses. Postoperatively she was
nauseated and lethargic and unable to take oral
medications. Phenytoin was given intravenously as
a loading dose of 1000 mg then as maintenance
of 100 mg every 8 hours. On day 2 she continued
to be lethargic, but her neurological examination
was nonfocal. Computerized topography (CT) of the
head showed expected postoperative changes. Her
phenytoin level was 23 µg ml−1 with a free level of
1.9 µg ml−1. On postoperative day three, she showed
improvement and was able to take oral medications.
Carbamazepine and lamotrigine were restarted at
her preoperative doses. During postoperative day 4,
phenytoin was discontinued, and she developed severe
bilateral upper extremity choreoathetosis without
facial dyskinesias. The total phenytoin level was
16 µg ml−1, the lamotrigine level was 13 µg ml−1
and the carbamazepine level was 7.9 µg ml−1. MRI
of the brain showed expected postoperative changes,
EEG showed no seizure activity. The next day she
continued to experience moderately severe chorea in
her hands and arms, which resolved 1 day later.
She was discharged home on her regular doses
of lamotrigine and carbamazepine with no further
seizures or abnormal movements.
Case 2
The second patient is a 47-year-old right-handed
woman with intractable right temporal lobe complex
partial seizures that started at age 36. Past medical
history included hypertension and a remote history
of alcoholism. There was no history of seizures
or abnormal movements in her immediate family
including her four healthy children.
She was initially treated with phenytoin without
adequate control. She had never experienced abnormal
movements despite multiple documented pheny-
toin levels above the therapeutic range (maximum
27 µg ml−1). Valproic acid was tried with partial
improvement. Phenobarbital provided no benefit
and she was unable to tolerate carbamazepine or
felbamate. She was evaluated for possible epilepsy
surgery but declined. Her lamotrigine was then added
to her phenytoin. Two weeks later she complained
of intermittent uncontrollable abnormal movements
involving her hands both at rest and with activity. Her
examination at that time showed normal coordination
and no abnormal movements. Her phenytoin level
was 21 µg ml−1 with a free level of 1.6 µg ml−1.
Lamotrigine level was 5.3 µg ml−1. At her next visit,
the patient and her husband again complained of
abnormal movements involving her hands and arms.
She noted difficulties with combing her hair, holding
glasses and cups in her hands. Her examination was
remarkable for frequent choreoathetoid movements of
her arms, which were worse on her right side. The
movements occurred at rest and with activity, she had
no facial dyskinesia or tremors. Apart from her chorea
her coordination and gait were normal.
Complete blood count, chemistry panel including
liver functions, antistreptolysin O titer and antinu-
clear antibody testing were negative. EEG showed
no seizure activity with the abnormal movements.
The patient was slowly tapered off phenytoin and
1 week later she reported marked improvement in
her movements and the disappearance of her func-
tional limitations, which was confirmed by physical
examination. She had no more chorea on lamotrigine
monotherapy and in a combination of lamotrigine and
topiramate for more than 2 years.
Case 3
A 3-year-old boy with Lennox–Gastaut syndrome was
admitted to our hospital for treatment of recurrent
minor motor seizures complicating a recent otitis
media. He had an uncomplicated pregnancy, with
normal development until the age of 10 months
when he developed frequent tonic posturing of the
neck during sleep. His symptoms rapidly evolved
into a mixture of daily generalized tonic–clonic,
atypical absence, tonic and atonic seizures and he
experienced developmental and motor regression.
There was no family history of seizures or abnormal
movements. Therapy with phenytoin did not help,
and no abnormal movements occurred. Phenobarbital
and clonazepine were tried, without improvement.
Lamotrigine replaced phenobarbital when he was
12 months old and his seizure control improved.
Later, a ketogenic diet, vigabatrin, topiramate and
felbamate were tried in various combinations with
some improvement.
At this admission he was still having seizures on
a combination of lamotrigine, clonazepam, felbamate
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Table 1: Anticonvulsants used by the three patients with and without chorea.
Patient Anticonvulsants (monotherapy Anticonvulsant combination Anticonvulsant removed after
or combinations) used when chorea developed which chorea improved
without chorea















CBZ: carbamazepine; LTG: lamotrigine; VPA: valproic acid; PHT: phenytoin; TPM: topiramate; PB: phenobarbital; VGT: vigabatrin.
and a ketogenic diet. He was started on phenytoin,
and discharged. Within a few weeks he developed
generalized choreoathetoid movements, which in-
creased with activity, and disappeared during sleep.
Movements were prominent in his limbs, without
orofacial involvement. MRI of the brain, muscle
biopsy, amino and organic acid analyses were normal.
EEG showed generalized slow spike and waves.
Phenytoin level was 11 µg ml−1, lamotrigine level
was not obtained. On discontinuation of phenytoin
there was significant improvement in his chorea.
DISCUSSION
Anticonvulsant-induced choreoathetosis was first re-
ported in 1962 with phenytoin8. A literature search
reveals about 80 cases. Reported patients are fre-
quently young and have organic brain abnormalities
including mental retardation1, 13. More than one half
of the cases have occurred in association with toxic
drug levels1, 9, 10. The use of phenytoin with other
medications was reported to an increase the risk of
developing abnormal movements1. Pharmacokinetic
interaction leading to increased free phenytoin level
was suggested as a plausible explanation1. Both
generalized and focal movements have been de-
scribed1, 11. Duration of dyskinesia has been variable,
but has often responded to discontinuation of the an-
ticonvulsants1, 12. Dyskinesias have most commonly
involved the limbs, but orofacial involvement has
been noted in some cases1, 11. Chorea as a result
of lamotrigine therapy was noted as a rare side
effect in trials (Lamotrigine package insert). Published
reports are limited to an abstract describing new
onset choreoathetosis in two young patients treated
with lamotrigine14. Recently Tourette’s syndrome was
reported in three patients taking lamotrigine15.
We describe three patients with new onset choreoa-
thetosis that developed while receiving lamotrigine
and phenytoin in combination therapy. The first
patient developed transient chorea when her usual
lamotrigine and carbamazepine, were supplemented
with phenytoin, which was loaded intravenously
shortly prior to chorea development. At the time
chorea developed, her phenytoin levels were in the
normal range (16 µg ml−1). Chorea related to the
phenytoin itself is unlikely, as she used it for 15 years
before without evidence of abnormal movements
despite higher levels. The combination of phenytoin
and carbamazepine was also used prior to the surgery
without any chorea (Table 1). Although intravenous
loading of phenytoin may cause transient chorea1, this
is unlikely in this patient as with the initial load and
at a higher phenytoin level (23 µg ml−1) she did not
have any chorea. On the combination of lamotrigine
and carbamazepine pre- and postoperatively she had
no abnormal movements. Prior to her surgery she
never used lamotrigine and phenytoin in combination.
Her chorea occurred with therapeutic drug levels of
these three anticonvulsants, levels which were similar
to or lower than previous levels which previously
produced no chorea.
The second patient used phenytoin for several years,
reaching supratherapeutic levels (up to 27 µg ml−1)
intermittently without developing abnormal move-
ments. When lamotrigine was added, she quickly
developed choreic hand and arm movements, which
resolved with phenytoin withdrawal. Subsequent
follow up for this patient showed no chorea on lamot-
rigine alone, or with a combination of lamotrigine and
topiramate (Table 1). In this patient it is also reason-
Anticonvulsants-induced chorea: a role for pharmacodynamic drug interaction? 599
able to conclude that neither lamotrigine nor phenytoin
alone produced chorea, but the combination did.
The third patient experienced the onset of choreoa-
thetosis on a combination of anticonvulsants which
included phenytoin and lamotrigine, in addition to
felbamate and topiramate. The abnormal movements
started shortly after adding phenytoin and significantly
improved when phenytoin was discontinued since this
patient used phenytoin in monotherapy prior to this
without any abnormal movements (Table 1). Chorea
is most likely due to the combination therapy. This
patient has similar risk factors to other children
described with drug-induced chorea4, 13, 14.
The mechanism by which these patients devel-
oped chorea is unknown. Pharmacokinetic interaction
between anticonvulsants causing elevated high pheny-
toin levels is unlikely in our patients as lamotrigine is
known not to elevate phenytoin levels20. In addition
phenytoin levels were not elevated (Table 2).
Table 2: Phenytoin and lamotrigine blood levels (in µg ml−1)




Two 21 (free level 1.6) 5.3
Three 11 NA
The pathophysiology of anticonvulsant-induced
dyskinesias in general is uncertain, although it
has been postulated that phenytoin may cause
chorea through enhancement of central dopaminergic
pathways in the basal ganglia1, 9. Lamotrigine is
known to inhibit glutamate release in the central
nervous system16, 17. In a mouse model of Parkinson’s
disease, lamotrigine was found to increase basal
ganglia dopamine activity leading to increased motor
activity19. This finding was explained by postulating
potentiation of the dopaminergic basal ganglia con-
nections through inhibition of glutamatergic cortico-
striatal pathways. This mechanism could also explain
the worsening of dyskinesia in two of 12 patients
with idiopathic Parkinson’s disease treated with
lamotrigine18. Combined lamotrigine and phenytoin
effects on central dopaminergic pathways might
explain why our patients developed chorea when
both anticonvulsants were present in combination.
Neither direct enhancement of dopaminergic activity
induced by phenytoin, or indirect enhancement by
lamotrigine alone was sufficient to provoke abnormal
movements. In combination, the effects of lamotrigine
and phenytoin appear to be additive or synergistic,
resulting in sufficient enhancement of dopaminergic
activity to provoke clinically apparent choreoathetosis,
this is rather a pharmacodynamic interaction between
both anticonvulsants. Removal of one of the medi-
cations was sufficient to ameliorate or eliminate the
clinical symptoms. These reported cases suggest that
patients treated with a combination of lamotrigine and
phenytoin may have an increased risk of developing
dyskinetic movement disorders.
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